Anatomy of female urinary system

Clinical trial tests a PARP inhibitor in urothelial cancer with DNA-repair defects

Apr 18, 2019

Urothelial carcinoma (UC), or bladder cancer, is the most common cancer of the urinary tract with limited treatment options. A new clinical trial aims to see how this type of cancer reacts to olaparib, a drug designed to target cancers that have defective DNA-repair mechanisms in their cells by inhibiting the action of PARP, an enzyme that can repair breaks in DNA. Read more...

Colon cancer cells

New study delivers chemotherapy to the liver for metastatic colorectal cancer patients

Apr 3, 2019

In some patients, colorectal cancer spreads only to the liver. Patients with previously treated colorectal cancer that has spread only to the liver may be eligible to participate in a new clinical trial at the NIH Clinical Center. Read more...

Patient-derived glioma stem cells

New clinical trial will determine if gliomas respond to immunotherapy

Apr 1, 2019

Gliomas make up about 80 percent of all malignant brain tumors. A new clinical trial at the Center for Cancer Research is investigating if the immunotherapy drug nivolumab is beneficial to patients with gliomas.  Read more...

Micrograph of a diffuse large B cell lymphoma

Trial results show that younger lymphoma patients respond well to ibrutinib

Mar 26, 2019

A recent clinical trial using the drug ibrutinib reveals that patients under age 60 with diffuse large B-cell lymphoma are much more likely to tolerate the drug – and respond to it – compared to those age 60 and older. Read more...

Chronic lymphocytic leukemia cells

New clinical trial recruits the immune system to attack chronic lymphocytic leukemia

Mar 15, 2019

Chronic lymphocytic leukemia (CLL) is cancer that develops in blood-forming cells in the bone marrow. A new clinical trial is testing a way to boost the body’s natural immune cells and recruit them to attack and kill marked leukemia cells. Read more...

Nanoparticles in the brain

Clinical trial studies antitumor effect of sunitinib in central nervous system sarcomas

Feb 4, 2019

A new clinical trial is testing a cancer drug, sunitinib, on recurrent gliosarcoma and previously treated sarcomas of the central nervous system. This drug has been studied in several other types of cancer, where it was able to inhibit factors that help tumors grow and spread. Investigators want to see if sunitinib can have the same antitumor effect on sarcomas and gliosarcoma of the brain and spinal cord. Read more...

T cells

Clinical trial finds combination therapy effective for some biliary cancer patients

Jan 28, 2019

Completion of a phase I/II clinical trial found that two of 20 patients with biliary tract cancer disease experienced a partial response to treatment with the immune checkpoint inhibitor tremelimumab combined with microwave ablation therapy. Further studies are needed to understand why just a few patients responded well to this combination treatment. Read more...

Jeremy Davis

New imaging technology to detect early-stage hereditary diffuse gastric cancer tested in clinical trial

Jan 24, 2019

Hereditary diffuse gastric cancer is a rare inherited condition caused by a mutation in the CDH1 gene. People who carry this genetic mutation are urged to have a screening endoscopy followed by surgery to remove the stomach. However, some patients elect to have regular endoscopic screenings to look for cancer. A new clinical trial is testing an imaging technology called confocal endoscopic microscopy (CEM) that may better detect cells in patients with the CDH1 mutation and potentially make a diagnosis during the endoscopy itself. Read more...

KRAS structure

Clinical trials evaluate T-cell transfer therapy for cancers with a mutated KRAS gene

Dec 17, 2018

KRAS mutations are present in up to a quarter of all human cancers, and eligible patients in a new clinical trial will undergo gene transfer therapy that uses their own blood cells. Investigators want to see if anti-KRAS T cells can make tumors shrink and whether this therapy has tolerable side effects.  Read more...

Boy playing with cars

Clinical trial studies new therapy in children and adults with neurofibromatosis-related GIST

Nov 28, 2018

Patients with neurofibromatosis type 1 (NF1) have an increased risk of developing gastrointestinal stromal tumors (GIST). There is currently no effective medical therapy for GIST that cannot be completely resected. Brigitte Widemann, M.D., Chief of the Pediatric Oncology Branch, is leading a study to see if NF1-related GIST responds to treatment with selumetinib, which blocks a signaling protein called MEK. Read more...

Pages